Kovai Medical

When is the next results date for Kovai Medical?

No Upcoming Board Meetings

Who are in the management team of Kovai Medical?

As of March 2022, the management team of Kovai Medical includes Managing Director Nalla G Palaniswami, Joint Managing Director Thavamani Devi Palaniswami, and several directors, along with independent directors and Company Secretary R Ponmanikandan.

As of March 2022, the management team of Kovai Medical includes the following individuals:<BR><BR>1. Nalla G Palaniswami - Managing Director<BR>2. Thavamani Devi Palaniswami - Joint Managing Director<BR>3. Arun N Palaniswami - Whole-time Director<BR>4. M C Thirumoorthi - Director<BR>5. Purani P Palaniswami - Director<BR>6. Mohan S Gounder - Director<BR><BR>Additionally, the board comprises several independent directors:<BR><BR>1. Kasi K Goundan - Independent Director<BR>2. M Manickam - Independent Director<BR>3. A M Palanisamy - Independent Director<BR>4. K Saminathan - Independent Director<BR>5. R Bhuvaneshwari - Independent Director<BR>6. A P Ammasai Kutty - Independent Director<BR>7. K.Kolandaswamy - Independent Director<BR><BR>Lastly, R Ponmanikandan serves as the Company Secretary and Compliance Officer.

What does Kovai Medical do?

Kovai Medical Center and Hospital Ltd is a mid-cap multi-speciality hospital based in Coimbatore, established in 1985, with a recent net sales of ₹357 Cr and a net profit of ₹55 Cr as of March 2025. The company has a market cap of ₹6,678 Cr and key financial metrics include a P/E ratio of 32.00 and a return on equity of 23.52%.

Overview: <BR>Kovai Medical Center and Hospital Ltd operates as a multi-speciality hospital in the healthcare industry and is categorized as a mid-cap company.<BR><BR>History: <BR>The company was incorporated in 1985 and began its hospital operations in 1990 with a flagship 200-bed multi-speciality hospital in Coimbatore. As of the latest quarterly results reported for March 2025, the company has shown significant financial performance.<BR><BR>Financial Snapshot: <BR>- Net Sales: 357 Cr (Quarterly Results - Mar 2025) <BR>- Net Profit: 55 Cr (Quarterly Results - Mar 2025) <BR>- Market Cap: Rs 6,678 Cr (Mid Cap) <BR><BR>Key Metrics: <BR>- P/E: 32.00 <BR>- Industry P/E: 54 <BR>- Dividend Yield: 0.16% <BR>- Debt-Equity: 0.07 <BR>- Return on Equity: 23.52% <BR>- Price to Book: 7.55 <BR><BR>Contact Details: <BR>Address: 99 Avanashi Road, Coimbatore, Tamil Nadu: 641014 <BR>Tel: 91-422-4323800/3083800 <BR>Email: secretarialdept@kmchhospitals.com <BR>Website: http://www.kmchhospitals.com

Has Kovai Medical declared dividend?

Kovai Medical Center & Hospital Ltd has declared a 100% dividend, amounting to ₹10 per share, with an ex-date of August 1, 2024. The company has shown strong total returns over various periods, with a 5-year total return of 839.69%.

Kovai Medical Center & Hospital Ltd has declared a 100% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 100%<BR>- Amount per share: 10<BR>- Ex-date: 01 Aug 24<BR><BR>Dividend Yield: 0.16%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 13.86%, with a dividend return of 0%, resulting in a total return of 13.86%.<BR><BR>Over the past year, the price return was 42.66%, the dividend return was 0.23%, leading to a total return of 42.89%.<BR><BR>For the 2-year period, the price return was 168.15%, the dividend return was 0.68%, culminating in a total return of 168.83%.<BR><BR>In the 3-year period, the price return was 327.22%, with a dividend return of 1.30%, resulting in a total return of 328.52%.<BR><BR>Over the last 4 years, the price return was 312.75%, the dividend return was 1.56%, leading to a total return of 314.31%.<BR><BR>In the 5-year period, the price return was 836.48%, with a dividend return of 3.21%, resulting in a total return of 839.69%.<BR><BR>Overall, Kovai Medical has declared a substantial dividend while also demonstrating impressive total returns across various periods, indicating strong financial performance and shareholder value enhancement.

Who are the peers of the Kovai Medical?

Kovai Medical's peers include Max Healthcare, Apollo Hospitals, Fortis Health, Narayana Hrudaya, Global Health, Yatharth Hospital, Indraprastha Medical, Artemis Medicare, and Dr. Agarwal's Eye. Among these, Max Healthcare and Apollo Hospitals show excellent management and growth, while Kovai Medical has below average growth and a good capital structure.

Peers: The peers of Kovai Medical are Max Healthcare, Apollo Hospitals, Fortis Health., Narayana Hrudaya, Global Health, Yatharth Hospit., Indrapr.Medical, Artemis Medicare, and Dr Agarwal's Eye.<BR><BR>Quality Snapshot: Excellent management risk is observed at Max Healthcare, Apollo Hospitals, Narayana Hrudaya, Global Health, and Indrapr.Medical, while Average management risk is found at Fortis Health., Yatharth Hospit., and Dr Agarwal's Eye, and the rest have Below Average management risk. Growth is Excellent at Max Healthcare and Apollo Hospitals, Good at Fortis Health., Narayana Hrudaya, Yatharth Hospit., and Indrapr.Medical, while Kovai Medical has Below Average growth and the rest have Below Average growth. Excellent capital structure is noted at Max Healthcare, Global Health, and Indrapr.Medical, while Average capital structure is found at Apollo Hospitals and Artemis Medicare, and Good capital structure is observed at Fortis Health., Kovai Medical, and Narayana Hrudaya, with the rest having Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Indrapr.Medical at 78.02%, while the lowest is Global Health at 4.29%. Kovai Medical's 1-year return of 46.73% is significantly higher than Global Health's but lower than Indrapr.Medical's. Additionally, Yatharth Hospit., Indrapr.Medical, Artemis Medicare, and Dr Agarwal's Eye have negative six-month returns.

Who are the top shareholders of the Kovai Medical?

The top shareholders of Kovai Medical include Kovai Purani Finance Private Limited with 36.96%, individual investors with 22.47%, and various institutional investors holding a total of 4.95%. Notably, there are no pledged promoter holdings.

The top shareholders of Kovai Medical include a mix of promoters and public investors. The majority of the shares are held by promoters, with Kovai Purani Finance Private Limited being the largest shareholder, owning 36.96% of the company. Additionally, individual investors collectively hold 22.47% of the shares. <BR><BR>In terms of institutional investors, there are 6 mutual fund schemes that hold a total of 3.67%, and 61 foreign institutional investors (FIIs) hold 1.28%. The highest public shareholder is Dsp Healthcare Fund, which has a holding of 1.63%. There are no pledged promoter holdings reported.

How big is Kovai Medical?

As of 24th July, Kovai Medical Center & Hospital Ltd has a market capitalization of 6,779.00 Cr, with recent Net Sales of 1,369.74 Cr and a Net Profit of 208.94 Cr.

As of 24th July, Kovai Medical Center & Hospital Ltd has a market capitalization of 6,779.00 Cr, categorizing it as a Mid Cap company.<BR><BR>In the latest four quarters, Kovai Medical reported Net Sales of 1,369.74 Cr and a Net Profit of 208.94 Cr.<BR><BR>The latest annual period for the balance sheet is March 2018, with Shareholder's Funds amounting to 288.56 Cr and Total Assets valued at 606.12 Cr.

Are Kovai Medical latest results good or bad?

Kovai Medical's latest Q2 FY26 results show a 25.09% increase in net profit to ₹57.23 crore and an 18.69% rise in revenue to ₹373.59 crore, indicating strong demand. However, the operating margin has decreased to 28.32%, raising concerns about cost management and operational efficiency.

Kovai Medical Center's latest results for Q2 FY26 present a mixed picture. On the positive side, the company reported a net profit of ₹57.23 crore, which is a 25.09% increase year-on-year. Additionally, revenue grew significantly by 18.69% year-on-year, reaching ₹373.59 crore, indicating strong demand for its healthcare services.<BR><BR>However, there are concerns regarding operational efficiency. The operating margin has decreased to 28.32%, down from 30.03% in the same quarter last year, reflecting rising cost pressures, particularly from employee expenses and interest costs. This margin compression, despite robust revenue growth, suggests that the company faces challenges in maintaining profitability.<BR><BR>Overall, while the revenue and profit figures are encouraging, the decline in operating margins raises important questions about cost management and operational efficiency moving forward. Investors may want to keep an eye on how the company addresses these margin pressures in future quarters.

Is Kovai Medical overvalued or undervalued?

As of November 10, 2025, Kovai Medical is considered very attractive in valuation, with a PE ratio of 29.89, an EV to EBITDA of 16.66, and a ROE of 21.05%, significantly lower than peers like Max Healthcare and Apollo Hospitals, while also outperforming the Sensex with an 11.59% return compared to its 5.09%.

As of 10 November 2025, Kovai Medical has moved from an attractive to a very attractive valuation grade. The company appears to be undervalued based on its current metrics. Key ratios include a PE ratio of 29.89, an EV to EBITDA of 16.66, and a ROE of 21.05%. <BR><BR>In comparison to its peers, Kovai Medical's PE ratio is significantly lower than that of Max Healthcare, which stands at 88.71, and Apollo Hospitals at 64.78, indicating a more favorable valuation. The company's recent stock performance has outpaced the Sensex over the last year, returning 11.59% compared to the Sensex's 5.09%, reinforcing the attractiveness of its current valuation.

How has been the historical performance of Kovai Medical?

Kovai Medical's historical performance from March 2013 to March 2018 shows strong growth in net sales from 297.01 Cr to 585.51 Cr, with total operating income reaching 592.37 Cr and profit after tax at 57.98 Cr. Despite rising expenditures and total liabilities of 606.12 Cr, the company maintained positive cash flow and a solid earnings per share of 52.99.

Answer:<BR>The historical performance of Kovai Medical shows a consistent growth trajectory in net sales, with figures rising from 297.01 Cr in March 2013 to 585.51 Cr in March 2018. Other operating income also increased, albeit from a negligible amount in earlier years to 6.85 Cr by March 2018. Total operating income followed a similar upward trend, reaching 592.37 Cr in March 2018. The company's total expenditure, excluding depreciation, rose to 463.26 Cr in March 2018, reflecting increased operational costs. Operating profit, excluding other income, was 129.11 Cr in March 2018, with a slight decrease in the operating profit margin to 21.79%. Profit before tax peaked at 89.44 Cr in March 2018, while profit after tax was recorded at 57.98 Cr, showing a slight decline from the previous year. The earnings per share (EPS) was 52.99, with a book value per share of 263.71. On the balance sheet, total liabilities increased to 606.12 Cr, driven by long-term borrowings of 164.56 Cr. Total assets also grew to 606.12 Cr, with cash and cash equivalents at 23.68 Cr by March 2018, indicating a positive cash flow trend despite a significant outflow from investing activities.<BR><BR>Breakdown:<BR>Kovai Medical's financial performance from March 2013 to March 2018 illustrates robust growth in net sales, which increased from 297.01 Cr to 585.51 Cr, alongside a rise in other operating income to 6.85 Cr. Total operating income reached 592.37 Cr, while total expenditure climbed to 463.26 Cr, reflecting the company's expanding operations. Operating profit, excluding other income, was 129.11 Cr, with a slight decrease in the operating profit margin to 21.79%. Profit before tax was 89.44 Cr, and profit after tax was 57.98 Cr, indicating a minor decline from the previous year. The earnings per share stood at 52.99, and the book value per share increased to 263.71. On the balance sheet, total liabilities rose to 606.12 Cr, primarily due to long-term borrowings of 164.56 Cr, while total assets matched this figure, with cash and cash equivalents at 23.68 Cr, reflecting a positive cash flow despite significant investment outflows.

Is Kovai Medical technically bullish or bearish?

As of December 3, 2025, Kovai Medical's trend has shifted to mildly bearish, supported by bearish signals from the MACD, KST, and Dow Theory, despite some mildly bullish indications from daily moving averages.

As of 3 December 2025, the technical trend for Kovai Medical has changed from mildly bullish to mildly bearish. The current stance is mildly bearish, driven by the weekly and monthly MACD and KST indicators, both indicating a bearish outlook. The Dow Theory also supports this bearish sentiment on both weekly and monthly time frames. While the daily moving averages show a mildly bullish signal, the overall trend is overshadowed by the bearish signals from the weekly Bollinger Bands and the lack of strong signals from the RSI. The recent price action reflects a decline from the previous close, further confirming the bearish trend.

Should I buy, sell or hold Kovai Medical?

Should I buy, sell or hold Kovai Medical?

Which are the latest news on Kovai Medical?

Why is Kovai Medical Center & Hospital Ltd falling/rising?

As of 18-Jan, Kovai Medical Center & Hospital Ltd's stock price is rising to 5,483.85, indicating a potential recovery in investor sentiment after recent declines. Strong fundamentals and increased investor participation support this upward trend despite the stock trading below its moving averages.

As of 18-Jan, Kovai Medical Center & Hospital Ltd's stock price is rising, currently at 5,483.85, reflecting a change of 5.55 (0.1%) upward. This rise can be attributed to a trend reversal after two consecutive days of decline, indicating a potential recovery in investor sentiment. Additionally, the stock outperformed its sector by 1.06% today, suggesting stronger performance relative to its peers.<BR><BR>The stock reached an intraday high of Rs 5665, which is a 3.41% increase, further supporting the notion of a rebound. Moreover, there has been a significant increase in investor participation, with delivery volume rising by 159.92% compared to the 5-day average, indicating growing interest among investors.<BR><BR>Despite the stock trading below its moving averages across various timeframes, the company's strong fundamentals, such as a high return on capital employed (ROCE) of 20.78% and a low debt-to-EBITDA ratio of 0.99 times, contribute positively to its valuation. The company has also reported impressive financial metrics, including the highest net sales of Rs 392.00 crore and a robust operating profit to interest ratio of 12.24 times.<BR><BR>Overall, while the stock has experienced declines over the past month and year, the recent positive performance and strong financial indicators suggest a favorable outlook, leading to the current rise in its stock price.